Recent Updates
Recently added Catalysts
PEPG Negative Sentiment Score: 20/100

PEPGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in PepGen, Inc. (PEPG) to Inquire About Their Rights in Class Action Lawsuit

Key Takeaway: Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against PepGen, Inc. on behalf of investors who purchased shares between March 7, 2024, and March 3, 2025. The complaint alleges that the company made false statements regarding the safety and effectiveness of its product PGN-EDO51 and the adequacy of the CONNECT2 study, leading to overstated clinical and regulatory prospects. Investors are encouraged to contact the firm to discuss their rights and participation options in the legal action. The deadline for appointing a lead plaintiff is August 8, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against PepGen, indicating potential legal troubles.
  • Allegations of materially false and misleading statements regarding the company's operations and prospects.
  • Concerns related to the CONNECT2 study's safety and effectiveness potentially affecting FDA approval.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PepGen (PEPG) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PepGen, Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). Investors have until August 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired PepGen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the class action lawsuit against PepGen about?

The lawsuit alleges PepGen made misleading statements about its business operations and drug effectiveness.

Who should contact Bragar Eagel & Squire?

Investors who purchased PepGen securities between March 7, 2024, and March 3, 2025, should reach out.

What is the deadline to apply as lead plaintiff?

Investors have until August 8, 2025, to apply for lead plaintiff status in the lawsuit.

How can I discuss my legal options?

Contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire by calling (212) 355-4648.

Is there a cost for consulting Bragar Eagel & Squire?

No, there are no costs or obligations for consulting the firm regarding your situation.

Last updated: Jul 20, 2025